Alnylam Pharmaceuticals' Strong Financial Performance and Insider Trading Activity

  • Alnylam Pharmaceuticals (NASDAQ:ALNY) reported adjusted earnings of 6 cents per share, surpassing expectations.
  • The company's total revenues reached $593.2 million, driven by strong demand for its newly approved drug, Amvuttra.
  • Despite positive financial results, ALNY's stock experienced a slight decrease, reflecting the volatile nature of biopharmaceutical stocks.

Alnylam Pharmaceuticals (NASDAQ:ALNY) is a biopharmaceutical company focused on developing RNA interference (RNAi) therapeutics. The company is a leader in this innovative field, aiming to treat genetic diseases by silencing specific genes. Alnylam's competitors include Ionis Pharmaceuticals and Moderna, which also explore genetic-based therapies.

On February 18, 2025, Kevin Joseph Fitzgerald, Alnylam's Chief Scientific Officer, sold 115 shares of the company's stock at $251.60 each. Despite this sale, Fitzgerald still holds 13,120 shares. This transaction comes after Alnylam's strong fourth-quarter 2024 performance, where earnings and revenues exceeded expectations.

Alnylam reported adjusted earnings of 6 cents per share, surpassing the Zacks Consensus Estimate of a 21-cent loss. This is a significant improvement from the previous year's loss of 77 cents per share. The company's total revenues reached $593.2 million, exceeding the anticipated $570 million, driven by a 30% rise in net product revenues.

The increase in product sales is largely due to strong demand for Amvuttra (vutrisiran), a newly approved drug. This contributed to a 35% year-over-year revenue growth from $439.7 million. Despite these positive results, ALNY's stock is currently priced at $250, reflecting a 2.52% decrease.

ALNY's stock has fluctuated between $249.16 and $259.95 during the trading day. Over the past year, it reached a high of $304.39 and a low of $141.98. With a market capitalization of approximately $32.36 billion, ALNY remains a significant player in the biopharmaceutical industry. Today's trading volume is 880,786 shares.
Alnylam Pharmaceuticals, Inc. View
Symbol Price %chg
207940.KS 1079000 1.02
068270.KS 186900 1.87
196170.KQ 361000 -2.49
091990.KQ 75900 0
ALNY Ratings Summary
ALNY Quant Ranking
Related Analysis

What Does Competitor’s Failure Mean to Alnylam Pharmaceuticals?

According to the announcement on Monday, BridgeBio Pharma, Inc. (NASDAQ:BBIO) acoramidis, the competitor of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), failed to significantly differentiate from placebo on 6MWD at 12 months in its Phase 3 trial in ATTR cardiomyopathy, the primary endpoint (p=0.76).

Despite this competitor disappointment, Alnylam Pharmaceuticals’ shares are weak, the possible reason of which can be the concerns that the unexpectedly strong performance seen in ATTRibute-CM's placebo group could similarly manifest in Apollo-B.

Analysts at Oppenheimer mentioned that they do not share the market's newfound skepticism and suggest buying the stock on weakness.